




BIOTECHNOLOGY




MARKET SIZE

India Biotechnology industry valuation (US\$ billion)




APPROVALS

Number of biologics and biosimilars approved in India





KEY TRENDS

Clinical trials market in India (US\$ billion)




Medical device market in India (US\$ billion)



GOVERNMENT INITIATIVES



Make in India



Biotech Parks



National Biopharma Mission



ADVANTAGE INDIA

- Skilled human capital:** With a total population of 1.4 billion, 47% being under the age of 25, India has a large pool of young and skilled workforce. India has a large reservoir of scientific human resources, including scientists and engineers.
- Government Support:** In February 2026, the Government of India introduced the Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) initiative under the Union Budget 2026-27, a five-year scheme with an outlay of US\$ 1.20 billion (Rs. 10,000 crore) aimed at strengthening India's position as a global manufacturing hub for biologics and biosimilars. Supported by the Department of Biotechnology (DBT), the ecosystem has benefited from enhanced research infrastructure, industry collaborations and innovation-driven initiatives aligned with national programmes such as AatmaNirbhar Bharat, Startup India and Make in India.
- FDI Policy:** 100% under automatic route for greenfield projects for pharmaceuticals; 100% under automatic route is allowed for the manufacturing of medical devices.
- Epidemiological factors:** The patient pool is expected to increase over 20% in the next 10 years, mainly due to a rise in population.